Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03066206 · ClinicalTrials.gov registry record · Phase 2
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT03066206: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT03066206 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03066206, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with an EGFR or HER2 exon 20 mutation that is stage IV or has come back (recurrent). Poziotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth..
Interventions
- DRUG Poziotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2017-03-17 |
| Est. Completion | 2026-02-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03066206
The ClinicalTrials.gov registry entry for NCT03066206 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Poziotinib is the first listed.
NCT03066206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03066206 about?
NCT03066206 is a clinical study titled "Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC". This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with an EGFR or HER2 exon 20 mutation that is stage IV or has come back (recurrent). Poziotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth..
What is the current status of trial NCT03066206?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2017-03-17. Estimated completion is 2026-02-16.
What interventions are being tested in trial NCT03066206?
The interventions under investigation include: Poziotinib (DRUG).
Who is sponsoring clinical trial NCT03066206?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.